Gemcitabine and Monoclonal Antibody Therapy in Treating Patients With Metastatic Cancer of the Pancreas
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die. Monoclonal antibodies such as trastuzumab can locate tumor cells
and either kill them or deliver tumor-killing substances to them without harming normal
cells. Combining monoclonal antibody therapy with chemotherapy may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of gemcitabine and trastuzumab in treating
patients who have metastatic cancer of the pancreas that overexpresses HER2/neu.